Search Results for

Showing 21 - 30 of 510 results
  1. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  2. ARVO Education

    ARVO Education Online Education Meet presentations Education Courses

  3. Contact Us

    Contact us ARVO Administrative Office ARVO 1801 Rockville Pike, Suite 400              Rockville, Md.  20852 USA Email: arvo@arvo.org   Telephone: +1.240.221.2900 Main Fax: +1.240.221.0370 Journals Fax: +1.240.221.0355   Contact the ARVO team Membership and general inquiries arvo@arvo.org     ARVO Foundation for Eye Research info@arvofoundation.org     Finance and accounting, including  accounts payable and receivable arvoaccounting@arvo.org    

  4. Telling the story of OCT

    Telling the story of OCT Optical coherence tomography (OCT) is a technology invented by ARVO members that helps preserve patients' sight, saves taxpayers billions of dollars and enables further discoveries in science and medicine. See how ARVO has shared the impact of OCT with vision scientists, patients, and policymakers.  OCT projects

  5. ARVO Foundation: Advancing science and careers

    ARVO Foundation Advancing science and careers Genentech AMD Research Fellowship recipients share their progress The Genentech Age-Related Macular Degeneration (AMD) Research Fellowships are awarded annually through the ARVO Foundation. The award supports two research fellowships for young investigators who are age 45 or younger, including one award for basic research in the understanding of AMD and one for translational AMD research focusing on therapeutics (not yet in clinical trials). The

  6. ARVO Foundation welcomes Chair Paul Sternberg, Jr.

    ARVO Foundation ARVO Foundation welcomes new chair Paul Sternberg, Jr. Paul Sternberg, Jr., MD, FARVO, will take the helm of the ARVO Foundation as chair of the Board of Governors in April. Sternberg has served as a Governor since 2014 and is a past ARVO Trustee representing the Retina Section. Sternberg is the G. W. Hale Professor of Ophthalmology at the Vanderbilt Eye Institute and chief medical officer and chief patient experience officer at Vanderbilt University Medical Center in Nashvil

  7. Spotlight on members: ONL Therapeutics

    Spotlight on members ONL Therapeutics: More than a one-shot wonder It’s a classic story: scientist discovers a compound with real therapeutic potential, only to have no idea how to move forward. Fortunately for David Zacks, MD, PhD, professor of ophthalmology and visual sciences at the University of Michigan Kellogg Eye Center, help was waiting on campus. Guided by the university’s technology transfer office, ONL Therapeutics was incorporated. And with Small Business Innovative Research (SBIR

  8. 5 members in 5 minutes

    5 members in 5 minutes Sharing vision research with new audiences Last year, ARVO launched its one-year Science Communication Training Fellowship (SciCommTF) program to train Members-in-Training from the U.S and outside the U.S. to become more effective communicators of vision research to various audiences. As one of their requirements, each fellow is responsible for developing and implementing an advocacy or outreach activity. Are you thinking about how you can share your research with patie